Targeted Nanopore Sequencing for Molecular Characterization of First-Line Drug Resistance and Treatment Outcomes Among Patients in the Republic of Congo
International Journal of Molecular Sciences · 2026
DOI: 10.3390/ijms27208999 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2026. Verfasst von Mita Naomie Merveille Dello und 16 weiteren Autor:innen. Beteiligte Einrichtung: Fondation Congolaise pour la Recherche Médicale, Brazzaville P.O. Box 2672, Congo. Hauptthemen laut MEDLINE: Mycobacterium tuberculosis, Antitubercular Agents, Tuberculosis, Multidrug-Resistant, Nanopore Sequencing. Die Arbeit nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: EDCTP3 under the Horizon Europe programme, CRDF Global, Central Africa Training Platform for Clinical Research on Infectious Diseases.
Abstract (Originalsprache)
Tuberculosis (TB) remains a major global public health concern, further complicated by the emergence and transmission of drug-resistant strains. Diversity within the Mycobacterium tuberculosis complex (MTBC) may also influence disease progression and treatment response. We conducted a longitudinal study among 126 Xpert MTB/RIF Ultra-confirmed TB patients enrolled and followed at the Antituberculosis Center of Brazzaville between July 2023 and November 2024. MTBC species were identified using the Genotype MTBC assay, and resistance-associated mutations in rpoB, katG, and embB were characterized by targeted Oxford Nanopore sequencing and interpreted using the WHO mutation catalogue and TB-Profiler. The overall treatment success rate was 81.7% (103/126). Among 109/126 samples successfully typed, M. tuberculosis accounted for 92.7% (101/109), Mycobacterium africanum for 3.7% (4/109), while mixed infection accounted for 0.9% (1/109) and inconclusive profiles for 2.8% (3/109). Resistance-associated mutations were assessed in 65 of the 126 enrolled patients with high-quality sequencing data. Among these 65 isolates, 32.3% (21/65) harbored resistance to at least one of the targeted first-line drugs, including isoniazid (23.1%; 15/65), rifampicin (15.4%; 10/65), and ethambutol (9.2%; 6/65). Multidrug-resistant TB was identified in 12.3% (8/65). The predominant mutations occurred at rpoB codon 435, katG codon 315, and embB codon 306. Treatment success was lower among patients infected with strains carrying a resistance-associated mutation (71.4%). Isoniazid resistance was associated with reduced odds of treatment success in unadjusted analysis (OR = 0.22, 95% CI: 0.05–0.93; p = 0.04). These findings suggest a considerable burden of genotypically predicted first-line drug resistance and support expanding molecular drug-susceptibility testing beyond rifampicin in TB surveillance and patient management in the Republic of Congo.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Fondation Congolaise pour la Recherche Médicale, Brazzaville P.O. Box 2672, Congo.
- Faculté des Sciences et Techniques, Université Marien Ngouabi, Brazzaville P.O. Box 69, Congo.
- Programme National de Lutte Contre la Tuberculose, Brazzaville P.O. Box 1066, Congo.
- Laboratoire National de Référence des Mycobactéries, Brazzaville P.O. Box 1066, Congo.
- Faculté des Sciences de la Santé, Université Marien Ngouabi, Brazzaville P.O. Box 2672, Congo.
- Centre de Recherches Médicales de Lambaréné, Lambaréné P.O. Box 1437, Gabon.
ORCID-Profile: Mita Naomie Merveille Dello, Freisnel Hermeland Mouzinga, Darrel Ornelle Elion Assiana, Claujens Chastel Mfoutou Mapanguy, Jabar Babatunde Pacôme Achimi Abdul, Salomon Bonsi Tchuandom, Alain Maxime Mouanga, Ayola Akim Adegnika, Francine Ntoumi
Förderung
- EDCTP3 under the Horizon Europe programme
- CRDF Global
- Central Africa Training Platform for Clinical Research on Infectious Diseases
- European and Developing Countries Clinical Trials Partnership 3
- National Science Foundation
Zitieren
APA
Dello, M. N. M., Mouzinga, F. H., Ngouama, B. B., Elion Assiana, D. O., Boumpouthoud, D. J. M., Djontu, J. C., Mfoutou Mapanguy, C. C., Ebata-Mboussa, E. F., Elenga, B. E., Achimi Abdul, J. B. P., Bonsi Tchuandom, S., Okemba-Okombi, F. H., Ayet, M. I., Nguimbi, E., Mouanga, A. M., Adegnika, A. A., & Ntoumi, F. (2026). Targeted Nanopore Sequencing for Molecular Characterization of First-Line Drug Resistance and Treatment Outcomes Among Patients in the Republic of Congo. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms27208999
Vancouver
Dello MNM, Mouzinga FH, Ngouama BB, Elion Assiana DO, Boumpouthoud DJM, Djontu JC, et al. Targeted Nanopore Sequencing for Molecular Characterization of First-Line Drug Resistance and Treatment Outcomes Among Patients in the Republic of Congo. International Journal of Molecular Sciences. 2026. doi:10.3390/ijms27208999
BibTeX
@article{Dello2026,
author = {Dello, Mita Naomie Merveille and Mouzinga, Freisnel Hermeland and Ngouama, Breli Bonheur and Elion Assiana, Darrel Ornelle and Boumpouthoud, Dechvie Jeannis Melissa and Djontu, Jean Claude and Mfoutou Mapanguy, Claujens Chastel and Ebata-Mboussa, Emmanuel Fonfon and Elenga, Beny Erudit and Achimi Abdul, Jabar Babatunde Pacôme and Bonsi Tchuandom, Salomon and Okemba-Okombi, Franck Hardain and Ayet, Michel Illoye and Nguimbi, Etienne and Mouanga, Alain Maxime and Adegnika, Ayola Akim and Ntoumi, Francine},
title = {Targeted Nanopore Sequencing for Molecular Characterization of First-Line Drug Resistance and Treatment Outcomes Among Patients in the Republic of Congo},
journal = {International Journal of Molecular Sciences},
year = {2026},
doi = {10.3390/ijms27208999}
}
EUVIMED